li001

A phase 2 trial found that combining Camrelizumab and Apatinib showed promising results in patients with refractory chordoma, a rare and aggressive spine cancer. The study included 33 patients. The combination achieved an objective response rate of 24.2% by RECIST 1.1 and 48.5% by Choi criteria, with a disease control rate of 90.9%. Median progression-free […]

Results from the phase 3 PSMAddition trial showed that adding lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) improved prostate-specific antigen (PSA) responses in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The randomized phase 3 study included 1,144 men with PSMA-positive mHSPC. Patients received either Pluvicto

A Phase 2 randomized study found that giving two preoperative doses of intravesical mitomycin-C before TURBT significantly reduced recurrence and progression in patients with non–muscle-invasive bladder cancer. The strategy is based on the idea that tumor manipulation during surgery can release cancer cells that later reimplant in the bladder. By administering chemotherapy before surgery, while

Interim results showed that detalimogene voraplasmid, a non-viral intravesical gene therapy, demonstrated encouraging activity and safety in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer who had already received extensive prior treatment. Among 125 evaluable patients, 54% achieved a complete response at some point during treatment, and most responses were seen by the first two-month assessment.